Clinical Trials
2 trialsNCT02167854 2021-07-09
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01598077 2020-12-19
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Novartis
Phase 1 Completed